Chronic Heart Failure With Reduced Ejection Fraction Clinical Trial
Official title:
Omecamtiv Mecarbil Post-trial Access Protocol for Subjects Completing Study 20110203 GALACTIC-HF
The primary objective of this study is to provide access to omecamtiv mecarbil for participants who have completed GALACTIC-HF 20110203.
This study was conducted by Amgen as the IND holder, with Cytokinetics as a collaborator. Due to the termination of the collaboration agreement between Amgen and Cytokinetics in May 2021 and subsequent transfer of the omecamtiv mecarbil IND from Amgen to Cytokinetics, Cytokinetics is now listed as the sponsor. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02861534 -
A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)
|
Phase 3 | |
| Completed |
NCT02226120 -
Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction
|
Phase 3 | |
| Recruiting |
NCT06148935 -
An Observational Study to Learn More About the Use of Vericiguat in Korean People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in Real-world Setting
|
||
| Active, not recruiting |
NCT05093933 -
A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)
|
Phase 3 | |
| Not yet recruiting |
NCT06195930 -
A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction
|
Phase 2 | |
| Completed |
NCT04836182 -
A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection Fraction
|
Phase 2 | |
| Recruiting |
NCT04983043 -
Efficacy and Safety of QiShen YiQi Dripping Pills in Chronic Heart Failure
|
Phase 2 | |
| Active, not recruiting |
NCT04840914 -
A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction
|
Phase 1 | |
| Completed |
NCT02768298 -
Exercise Capacity Study of LCZ696 vs. Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction.
|
Phase 4 | |
| Active, not recruiting |
NCT05974189 -
The VERIFY Study: An Observational Study Called VERIFY to Learn More About the Use of Vericiguat in People With Chronic Heart Failure With Reduced Ejection Fraction
|
||
| Recruiting |
NCT05553886 -
S086 Tablets for Chronic Heart Failure With Reduced Ejection Fraction
|
Phase 3 | |
| Completed |
NCT02900378 -
randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure
|
Phase 3 | |
| Recruiting |
NCT05658458 -
A Study to Learn How Well the Drug Vericiguat Works and How Safe it is Under Real World Conditions in Indian Participants After Worsening of a Long-term Heart Condition in Which the Left Side of the Heart Does Not Pump Blood as Well as it Should (Chronic Heart Failure With Reduced Ejection Fraction)
|
Phase 4 | |
| Recruiting |
NCT05728502 -
An Observational Study, Called VERI-China, to Learn More About How Well Vericiguat Works and How Safe it is in Real-world Setting in People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in China
|
||
| Active, not recruiting |
NCT06363110 -
An Observational Study to Learn More About Vericiguat Treatment Patterns and Its Safety in People With Chronic Heart Failure With Reduced Ejection Fraction in Routine Medical Care in the United States
|